Vaping and Coronavirus

[theclearspot]

Hi,I was reading this about risks with vaping and Coronavirus. Seems to weaken immune system so making you more likely to contract Covid. I switched from smoking to vaping a couple of years back which certainly helped mu lungs.
Thoughts?...


https://www.scientificamerican.com/...-the-risk-of-a-severe-coronavirus-infection1/

 

[Jellyfish]

Time to switch back.

 

[Snook]

I stopped vaping pens w oil about 3 months ago. It was starting to make my lungs feel heavy. At the same time backed off 99% of joints and burning in general : there's always the time when someone says "YOU GOTTA TRY THIS!" even at my age that still happens...

 

[theclearspot]

Time to switch back.

 

[flylowgethigh]

Smoking yes, not sure about vaping being damaging if done right. If I smoke a rosin soaked joint (reefer), my lungs feel heavy also. I think it is the sticky oil condensing there. You now how sticky oil is, right?

I know I have damaged my lungs with past practices, but I think vaping is actually helping them to heal. I still usually have a dissolved O2 of 91, but my lungs feel so good I do not have to use the corticosteriod inhaler.

What I do now, since I upgraded to a Hybrid Volcano with a whip, is turn the heat up to 400*, and put the chamber on for about 10 seconds to heat the material. Then turn on the fan and blast the evaporated terps and some actives into my lungs with a power hit. 2-3 seconds later, what a rush! Take off the chamber to stop heat transfer.

Let that rush settle in and re-attach the chamber, let it sit about 5 seconds cause it already has some heat, and repeat the power hit.

That's it. That gram or so is finished as far as sucking the terps off is concerned. I put that ABV into a container, and when it is full enough, make butter and some kick-ass cookies.

The reason I only do 2 hits, and why the second is only heated for 5 seconds, is I suspect something from the plant is starting to cook off. Maybe chlorophyl, as the color of the material does change to a darker green, and if I vape it again or just put the chamber on the volcano, it will turn brown. I seem to be very sensitive to chlorophyl, or whatever that smelly stuff is that remains, that you can smell after the second hit when the ABV is still warm. Makes me hack and cough.

When I was using bags on the volcano Digit, I was adjusting the temp down to avoid releasing that stink as the bag filled. It isn't as simple with a bag, especially the big ones I was using at the end, because the heat builds up and the stink gets released into the bag, to contaminate the sweet aromatic essential oil terps that came off initially. 365* seemed OK, but still not near as nice as just heating and blowing off the terps and vapors into a whip.

That ABV is still green, but when cooled down is almost bland to smell. My estimate is 75% of the actives are still there too, based on some ABV analysis that has been published. I would love to analyze mine, because it still has the stink, just waiting to be heated and jump off. My guess is stink = chlorophyll. I do jar cure BTW.

If I turn the temp to 420*, and fill a bag the effects of the high are much stronger. Maybe from the coughing that ensues. Vaping rosin doesn't make stink, er I mean cough, even at 440*.

I started toking at 16, almost 50 years ago. So so much more to this, than just twisting a doob from a bag of "green".

If I avoid that hacking from whatever it is that stinks, my lungs feel great. There is something coming off, especially on the first hit, that is magic.

 

[Gry]

Have well compromised immune system from
a variety of respiratory complications.

With Covad concerns as they are,
I mix extract with olive oil, and sublingual it.
Feels and comes on much like smoking.
It gives me what I need without additional
stress.
Best of wishes to each.

 

[Jellyfish]

I don't believe smoking weed hurts your lungs at all, unless you ALSO smoke tobacco or have some pre-existing condition.

 

[theclearspot]

'What I do now, since I upgraded to a Hybrid Volcano with a whip, is turn the heat up to 400*, and put the chamber on for about 10 seconds to heat the material. Then turn on the fan and blast the evaporated terps and some actives into my lungs with a power hit. 2-3 seconds later, what a rush! Take off the chamber to stop heat transfer.

Let that rush settle in and re-attach the chamber, let it sit about 5 seconds cause it already has some heat, and repeat the power hit.'



I have a Volcano also. I didnt quite follow that- do you mean you dont use the plastic bag?

 

[flylowgethigh]

'What I do now, since I upgraded to a Hybrid Volcano with a whip, is turn the heat up to 400*, and put the chamber on for about 10 seconds to heat the material. Then turn on the fan and blast the evaporated terps and some actives into my lungs with a power hit. 2-3 seconds later, what a rush! Take off the chamber to stop heat transfer.

Let that rush settle in and re-attach the chamber, let it sit about 5 seconds cause it already has some heat, and repeat the power hit.'



I have a Volcano also. I didnt quite follow that- do you mean you dont use the plastic bag?

Correct. The fan runs through the material only enough to fill my lungs twice. On the second hit I carburete at the end. Only doing one hit a lot, I am pretty well medicated on one.

The Hybrid has a heated chamber that heats pretty fast, so running hot air through it only helps keep the evaporates flying.

I think a Digit would benefit from a heated chamber. Just adapting a whip, and it will fit, isn't the same. Bags are not as controllable, or flavorful, as the whip on a power hit.

https://cdn.shopify.com/s/files/1/0209/9072/products/[email protected]

Have you seen their new setup? The bottom of the material chamber contacts the top of the heater tube on the base, allowing convection heat to make the chamber hot - fast. They had to change the way the chamber attaches to make it secure, and keep the hot chamber from burning you when you remove and open it. This is way better than a Digit IMO. That whip attachment will fit the older chambers.

 

[Snook]

I don't believe smoking weed hurts your lungs at all, unless you ALSO smoke tobacco or have some pre-existing condition.

Not at all!?? Come on JF.

Yes there is no nicotine but tar is huge in the lungs, even with MJ.
I believe vaping oils is even more invasive. We were ment to breath only air and even that in some places isnt the best for the lungs. Underlying factors make it all worse if one inhales any kind of 'smoke'.


I'd like to believe that the tar lining in my lungs will deter viruses but dont 'really' believe it.

 

[ozzieAI]

I doubt it matters if you smoke, vape or ingest it does affect the immune system...if your ECs is activated then...

Immunoregulatory Role of Cannabinoids during Infectious Disease


https://www.karger.com/Article/Fulltext/481824

Abstract
Although the endocannabinoid system (ECS) is involved in the regulation of several physiological processes, including sleep and the immune response, its role during infections has not been fully studied. It is well known that the use of this drug increases susceptibility to infections because of the impact on the modulation of the immune system. Concerning the medicinal or recreational use of marijuana, its influence on the course of an infection, whether this has been caused by bacteria, viruses, parasites, and to a lesser degree, fungi, has been reported. Furthermore, there is evidence suggesting the involvement of the ECS in the control and elimination of infectious agents such as bacteria, viruses, and some protozoa; in the case of fungi, few studies are available so far. The purpose of this review is to present the existing studies related to infections and the ECS, the microbicidal effects of compounds isolated from Cannabis sativa, and the association between marijuana use and the development of rare pathologies in specific diseases.
© 2017 S. Karger AG, Basel

Influenza
The administration of THC could be harmful for a host infected with the influenza virus. As reported in studies on mice, THC administration after an immune challenge with influenza virus A/PR/8 resulted in increased viral loads, higher hemagglutinin 1 expression, and diminished CD4+ and CD8+ lymphocyte and macrophage recruitment into the lungs [77]. Some of these effects were observed in an opposite manner when CB1 and CB2 knockout mice were infected, i.e., showing increased CD4+ lymphocyte recruitment, IFN-γ levels, and lung inflammation, higher than in control WT mice [78]. Other immune parameters affected include cytokine secretion by CD4+ T cells and NK cells, besides a lower overall percentage of subpopulations of antigen-presenting cells present in the lungs of infected mice [79]. The observed results demonstrate that THC administration diminishes the immune response against the influenza virus.

Concluding Remarks
It is well known that the immune system interacts with the nervous, immune, and endocrine systems, now considered as the neuroimmunoendocrine network. In this sense, ECS activation could be considered an important factor in the study of an effective or deficient immune response against infectious diseases. It should be highlighted that ECS activation might also present complex interactions during the course of an infection.

In this review, the in vitro evidence we have presented suggests that contact with cannabinoid compounds can affect different types of infectious agents, by allowing their replication or by eliminating them. This supports the idea of existing cannabinoid receptors infecting pathogens and that their activation may be responsible for previously mentioned effects, pointing to a new biological function of ECS activation. The immune system is responsible for dealing with foreign agents and their clearance, but, when the ECS is activated, the final result is sometimes different from what would be expected, i.e., the survival of infectious agents within the host.

In the case of bacteria, in vitro and in vivo tests present opposite effects, meaning that while in vitro studies showed cannabinoid compounds exerting antibacterial effects [6,30,54], in vivo tests showed increased host mortality. In the case of infection with L. pneumophila, this effect is due to immune system malfunction, caused by a compromised Th1 protective response [37] or because macrophage functions are inhibited [41], thereby supporting the notion that ECS activation contributes to the function of the immune system. Interestingly, when LPS was injected into mice, the results were similar to the results reported in vitro, because the lack of cannabinoid receptors induced an ineffective immune response [32,33].

Similarly, in the case of viral infections, the contact of viral particles with cannabinoid compounds makes them capable of negatively modulating some immune response parameters. During HIV infection, there is a reduction in CD4+ T cells and IFN-γ concentration [69]. During SIV infection, the activity of NK cells is inhibited [68], resulting in increased host mortality [63,65,66], and, in an influenza virus infection, the viral load is also increased [77]. In the studies in vitro, different cannabinoids increased HCV [59] and HSV replication [60,61]. On the other hand, the use of cannabinoids during an infection with Theiler's virus, an experimental model of MS, showed that cannabinoid agents such as WIN 5,212-2, ACEA, and JWH-015 may be good therapeutic targets for treating MS due to the fact that they promote remyelination [81].[/QUOTE]

 

[mean mr.mustard]

Well that's depressing.

I need to smoke a joint now.

I thought that propylene glycol was used to kill germs in hospital ventilation systems...?

 

[theclearspot]

Correct. The fan runs through the material only enough to fill my lungs twice. On the second hit I carburete at the end. Only doing one hit a lot, I am pretty well medicated on one.

The Hybrid has a heated chamber that heats pretty fast, so running hot air through it only helps keep the evaporates flying.

I think a Digit would benefit from a heated chamber. Just adapting a whip, and it will fit, isn't the same. Bags are not as controllable, or flavorful, as the whip on a power hit.

https://cdn.shopify.com/s/files/1/0209/9072/products/[email protected]

Have you seen their new setup? The bottom of the material chamber contacts the top of the heater tube on the base, allowing convection heat to make the chamber hot - fast. They had to change the way the chamber attaches to make it secure, and keep the hot chamber from burning you when you remove and open it. This is way better than a Digit IMO. That whip attachment will fit the older chambers.

Thanks for that, so what you are saying is that the short sharp blast is better for the lungs than a few bag fulls from the vape? I have the old model Volcano, im not sure what a whip is.

 

[Gry]

CME / ABIM MOC / CE
Vaping and Lung Injury Recharacterized in Older Adults

Clinical Context

E-cigarette or vaping product use-associated lung injury has persisted as a national health crisis in the United States, with 2409 cases of EVALI hospitalizations reported to the Centers for Disease Control and Prevention (CDC) by December 10, 2019.[1] A total of 52 deaths had been associated with EVALI as of that time. According to results from a previous study by Siegel and colleagues, which was published in the October 18, 2019 issue of Morbidity and Mortality Weekly Report,[2] the median age of EVALI cases was 24 years, and more than three-quarters of patients had used products containing tetrahydrocannabinol.
Almost all (95%) patients with EVALI initially presented with pulmonary symptoms, but 77% had gastrointestinal symptoms (ie, abdominal pain, vomiting, diarrhea) as well. Constitutional symptoms such as fever and weight loss were noted among 85% of patients with EVALI. Approximately half of all patients with EVALI had tachycardia and tachypnea.

A laboratory workup directed toward potential infectious agents, such as influenza and common bacterial causes of pneumonia, should be considered, and all patients with possible EVALI should undergo chest radiography. Chest computed tomography has demonstrated bilateral ground glass opacities in some cases of negative chest radiography.
Nearly all (96%) patients with EVALI in one series were hospitalized. Patients with EVALI and hypoxemia, respiratory distress, or other illnesses that might compromise pulmonary function should be admitted. Treatment of EVALI can include corticosteroids, antibacterial drugs, and antiviral drugs, depending on the patient’s clinical presentation.
Close follow-up after the acute symptoms of EVALI have improved is important, and the current guidelines as reported by Evans and colleagues update previous recommendations in this domain.
Synopsis and Perspective

Patients who were rehospitalized or who died after being treated for EVALI were more likely to have been older and to have had at least one chronic illness, the CDC reported.
In response to these findings, the CDC has issued interim guidance recommending confirmation of patients' medical stability for 24 to 48 hours before discharge, outpatient follow-up of patients within 48 hours after discharge, and follow-up with a pulmonologist within 2 to 4 weeks after discharge.
According to the CDC,[3] 2561 cases of EVALI and 55 deaths have been reported as of December 27, 2019, and numbers continue to rise.
These findings underscore the need for incorporating measures that "might minimize EVALI patients' risk for rehospitalization and death, especially among patients with chronic conditions," the authors wrote.
Christina A. Mikosz, MD, and colleagues from the CDC's Lung Injury Response Epidemiology/Surveillance Task Force partnered with state health departments to develop a voluntary reporting service to collect data "on confirmed and probable hospitalized or deceased EVALI patients."
Using data reported to the CDC as of December 10, 2019, they compared the clinical characteristics of patients with EVALI who were rehospitalized or died after hospital discharge with those of patients with EVALI who were neither rehospitalized nor died after hospital discharge (comparator group). The findings were published January 3 in Morbidity and Mortality Weekly Report.[4]
Data from 2409 cases that required hospitalization were evaluated, including 52 deaths. The researchers found that among the 1139 patients discharged before October 31, 2019, 31 (2.7%) were rehospitalized, and 7 (13.5%) died after discharge. The median interval from discharge to readmission and from discharge to death was 4 days and 3 days, respectively. The comparator group included 768 patients with EVALI who were also discharged before October 31, 2019, but who were not rehospitalized and who did not die.
Mikosz and colleagues found that 70.6% of patients who were rehospitalized and 83.3% of patients who died had one or more chronic conditions compared with 25.6% of patients in the comparator group. Chronic conditions included cardiac disease, chronic pulmonary disease (eg, chronic obstructive pulmonary disease and obstructive sleep apnea), and diabetes.
Further, patients who died after their initial visit were more likely to be older (median age, 54 [range, 34-75] years). All required intubation and mechanical ventilation during their initial hospital visit. Duration of initial hospitalization and use of corticosteroids or antibiotics were similar for all 3 groups.
Given that most rehospitalizations occurred within 4 [range, 2-20] days after initial discharge, the authors suggested that "ensuring clinical stability before discharge as well as postdischarge follow-up optimally within 48 hours might minimize risk for rehospitalization and death, especially among patients with chronic conditions."
Findings Prompt New Guidance
In response to the finding by Mikosz and colleagues, the CDC, in consultation with the Lung Injury Response Clinical Working Group, has provided updated interim guidance for the management of patients with EVALI.[4] These new recommendations include the following:

• Confirmation of stable vital signs for ≥ 24 to 48 hours before discharge
• Follow-up within 48 hours of discharge (previous recommendation was within 2 weeks of discharge)
• Focused management of comorbidities and coordination of posthospitalization specialty care
• Ensuring access to mental and behavioral health services after discharge

The authors have disclosed no relevant financial relationships.
Highlights

• The new guidelines update previous guidelines regarding the best practice in follow-up of patients with EVALI. The current guidelines were developed in response to research that demonstrated a median interval from hospital discharge to readmission of 4 days and a median interval from discharge to death of 3 days among high-risk patients with EVALI.
• Many of these patients who were rehospitalized or died had chronic pulmonary or cardiac conditions, or diabetes, and these patients were also older.
• Patients with EVALI should be stable for discharge without clinical significant fluctuations in vital signs for 24 to 48 hours before the actual discharge time.
• Rehospitalization has been associated with a return to using vaping products immediately after discharge, so patients with EVALI should receive education and support to quit as inpatients. A behavioral health consultation may be helpful for these patients.
• There are no FDA-approved medications for persons < 18 years old to assist in tobacco or nicotine cessation, but adolescents should be offered counseling services to help them quit.
• Although the precise benefits of corticosteroids for EVALI remain largely unknown, many patients may not continue the tapering dose of corticosteroids after hospital discharge. Meeting with an inpatient pharmacist before discharge is recommended to stop this trend.
• Patients discharged after EVALI should see a primary care provider or pulmonary medicine specialist within 2 days of the discharge date. This significantly increases the recommended follow-up period, which was previously 1 to 2 weeks.
• Checking in on the patient remotely via phone or text or home visits from the healthcare team are also good care strategies.
• Follow-up with a pulmonary specialist should occur within 2 to 4 weeks after the discharge with the diagnosis of EVALI.
• Ongoing treatment with addiction medicine and behavioral health should also be considered.

Clinical Implications

• The median age of EVALI cases reported to the CDC in October 2019 was 24 years, and more than three-quarters of patients had used products containing tetrahydrocannabinol. Gastrointestinal and constitutional symptoms are common among patients with EVALI. Patients with suspected EVALI should receive chest radiography, and treatment can include corticosteroids, antibacterial drugs, and antiviral drugs.
• The current recommendations call for follow-up with a primary care provider or a pulmonary medicine specialist within 48 hours after hospital discharge related to EVALI.
• Implications for the Healthcare Team: The healthcare team needs to work together to maintain adherence and stop vaping among patients treated for EVALI.

Earn Credit

Authors: News Author: Jennifer Garcia; CME Author: Charles P. Vega, MDFaculty and Disclosures
CME / ABIM MOC / CE Released: 2/21/2020
Valid for credit through: 2/21/2021
https://www.medscape.org/viewarticle/925373

 

[flylowgethigh]

Thanks for that, so what you are saying is that the short sharp blast is better for the lungs than a few bag fulls from the vape? I have the old model Volcano, im not sure what a whip is.

Look at that picture I posted. The material chamber is on the Volcano, and it twists on so there is a good heat transfer contact for the chamber, and it stays tight. The thing on the chamber is the whip adapter, with the hose and end. This is called a "whip". You can also rig up a bong deal in line if you want.

As for the blasts... Not quite. My position is I like ingesting the global flower of goodness, and it's effects. My lungs prefer I vaporize only the terps and whatever goodness can be drawn out with them, without awakening the coughing compound of evil spirits. Kind like going through the Dwarf's cave without stirring the Balrog.

I am not sure what the compound is that triggers a cough, but I suspect plant material like chloriphyll. Maybe that nasty smell is water soluble, and a bong in-line would stop that. Or a Magma. I dunno.

The method I describe is how I am doing it. This AM, I did a couple that way, and decided since I am about to go out and mow some lawn (mindless activity if there ever was one), I loaded a bowl of some Royal Wedding (Indica dope) and turned the temp up to 426*, for the coup de grass (so to speak). Then I typed this, so pls understand.

I let the material chamber sit on the heat for about 15 seconds, started sucking on the whip, turned on the fan, and filled my lungs in one hit with all the goodness that gram has.

As you hold that hit in, the ears start buzzing, checker flags start appearing in the vision, which is kinda narrowing. I do this while leaning on the counter so there is no risk of passing out. In other words, a rush. That second hit will only introduce coughing, so put that ABV away.

That is what I mean, and no coughing involved. Sometimes the terps, which are light like solvents, seem to knock loose the tar lining my lungs, cause my airways feel open. I sometimes might hack up some mucus on the first hit of the morning, clear and sticky, which being out of there really makes the airways feel open and fresh.

Getting high and feeling good. I love that Hybrid with the heated chamber. Maybe the Arize does this also, as I have heard good reviews. Somebody needs to make a PID chamber to sit on top of the earlier Volcano models, that has the same exit, or a 14* whatever, cuse heating the material then blowing hot air through it to shed the evaporated goodies, is the bomb for my lungs.

If that seems wasteful, it's not. My main deal is the cookies made from the ABV. What is wasteful to me is decarbing good flower and just throwing away the terps. I may or may not decarb the ABV, but the cookies seem a tad stronger when I do.

 

[hard rain]

I doubt it matters if you smoke, vape or ingest it does affect the immune system...if your ECs is activated then...

Immunoregulatory Role of Cannabinoids during Infectious Disease


https://www.karger.com/Article/Fulltext/481824

Abstract
Although the endocannabinoid system (ECS) is involved in the regulation of several physiological processes, including sleep and the immune response, its role during infections has not been fully studied. It is well known that the use of this drug increases susceptibility to infections because of the impact on the modulation of the immune system. Concerning the medicinal or recreational use of marijuana, its influence on the course of an infection, whether this has been caused by bacteria, viruses, parasites, and to a lesser degree, fungi, has been reported. Furthermore, there is evidence suggesting the involvement of the ECS in the control and elimination of infectious agents such as bacteria, viruses, and some protozoa; in the case of fungi, few studies are available so far. The purpose of this review is to present the existing studies related to infections and the ECS, the microbicidal effects of compounds isolated from Cannabis sativa, and the association between marijuana use and the development of rare pathologies in specific diseases.
© 2017 S. Karger AG, Basel

Influenza
The administration of THC could be harmful for a host infected with the influenza virus. As reported in studies on mice, THC administration after an immune challenge with influenza virus A/PR/8 resulted in increased viral loads, higher hemagglutinin 1 expression, and diminished CD4+ and CD8+ lymphocyte and macrophage recruitment into the lungs [77]. Some of these effects were observed in an opposite manner when CB1 and CB2 knockout mice were infected, i.e., showing increased CD4+ lymphocyte recruitment, IFN-γ levels, and lung inflammation, higher than in control WT mice [78]. Other immune parameters affected include cytokine secretion by CD4+ T cells and NK cells, besides a lower overall percentage of subpopulations of antigen-presenting cells present in the lungs of infected mice [79]. The observed results demonstrate that THC administration diminishes the immune response against the influenza virus.

Concluding Remarks
It is well known that the immune system interacts with the nervous, immune, and endocrine systems, now considered as the neuroimmunoendocrine network. In this sense, ECS activation could be considered an important factor in the study of an effective or deficient immune response against infectious diseases. It should be highlighted that ECS activation might also present complex interactions during the course of an infection.

In this review, the in vitro evidence we have presented suggests that contact with cannabinoid compounds can affect different types of infectious agents, by allowing their replication or by eliminating them. This supports the idea of existing cannabinoid receptors infecting pathogens and that their activation may be responsible for previously mentioned effects, pointing to a new biological function of ECS activation. The immune system is responsible for dealing with foreign agents and their clearance, but, when the ECS is activated, the final result is sometimes different from what would be expected, i.e., the survival of infectious agents within the host.

In the case of bacteria, in vitro and in vivo tests present opposite effects, meaning that while in vitro studies showed cannabinoid compounds exerting antibacterial effects [6,30,54], in vivo tests showed increased host mortality. In the case of infection with L. pneumophila, this effect is due to immune system malfunction, caused by a compromised Th1 protective response [37] or because macrophage functions are inhibited [41], thereby supporting the notion that ECS activation contributes to the function of the immune system. Interestingly, when LPS was injected into mice, the results were similar to the results reported in vitro, because the lack of cannabinoid receptors induced an ineffective immune response [32,33].

Similarly, in the case of viral infections, the contact of viral particles with cannabinoid compounds makes them capable of negatively modulating some immune response parameters. During HIV infection, there is a reduction in CD4+ T cells and IFN-γ concentration [69]. During SIV infection, the activity of NK cells is inhibited [68], resulting in increased host mortality [63,65,66], and, in an influenza virus infection, the viral load is also increased [77]. In the studies in vitro, different cannabinoids increased HCV [59] and HSV replication [60,61]. On the other hand, the use of cannabinoids during an infection with Theiler's virus, an experimental model of MS, showed that cannabinoid agents such as WIN 5,212-2, ACEA, and JWH-015 may be good therapeutic targets for treating MS due to the fact that they promote remyelination [81].

[/QUOTE]
Thanks for posting but that article may prompt me to give up cannabis for the duration of the virus.
Scary stuff indeed.

 

[theclearspot]

Thanks for posting but that article may prompt me to give up cannabis for the duration of the virus.
Scary stuff indeed.[/QUOTE]

Yes, I have switched to edibles...which dont work for me but I have a bad chest.

 

[CosmicCharlie]

According to the article any Cannabis product would have an affect on the Immune System.

However, being that this Virus affects the Lungs badly once it gets there then smoking and vaping are not really recommended.

With some Terpenes acting as expectorants I really wonder if that is true though?

They might help keep the Virus from ever entering the Lungs?

 

[I'mback]

Well that's depressing.

I need to smoke a joint now.

I thought that propylene glycol was used to kill germs in hospital ventilation systems...?

Yes it does, still does and is still in use

 

[I'mback]

Edibles and "mari-pills" to the rescue.

I started vaping 10 years ago and I can count on one hand the amount of colds I have caught since. In the beginning, vapers thought is was there imagination (no longer catching colds) but, as years revealed themselves, we weren't imagining things.